CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

nasal pharyngeal (NP) swab samplesWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2946 peripheral blood draw Wiki 1.00

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D007239 Infection NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 The Use of Peripheral Blood Specimens From Patients Suspected of Having SARS-CoV-2 Infections in Research Studies Intended to Support the Development of COVID-19 Detection Methods, Treatments, and/or Vaccines

Invivoscribe, Inc. and its wholly owned subsidiary LabPMM, LLC are collecting peripheral blood specimens from patients with suspected SARS-CoV-2 viral infections. These donors will be from a population of patients who are already providing nasal pharyngeal (NP) swab samples in universal transport media (UTM) for COVID-19 testing at LabPMM LLC. Specimens meeting this research protocol's inclusion criteria may be evaluated with various molecular techniques in order to identify nucleic acid sequences, antibodies, and/or antigens with the potential of being used to develop novel SARS-CoV-2 detection methods and COVID- 19 treatments and/or prevention methods (e.g. drug or vaccine development).

NCT04391400 SARS-CoV-2 Diagnostic Test: nasal pharyngeal (NP) swab samples Diagnostic Test: peripheral blood draw
MeSH:Infection

Primary Outcomes

Description: This research protocol describes the collection and analysis of peripheral blood samples to: Identify nucleic acid sequences that may be used aide in the development of SARSCoV- 2 detection methods. Identify antibodies that may be used aide in the development of SARS-CoV-2 detection methods. Identify antigens that may be used aide in the development of SARS-CoV-2 detection methods. Identify nucleic acid sequences that may be used aide in the development of COVID- 19 treatments and/or vaccines. Identify antibodies that may be used aide in the development of COVID-19 treatments and/or vaccines. Identify antigens that may be used aide in the development of COVID-19 treatments and/or vaccines.

Measure: Identification of nucleic acid sequencing, antibodies and antigens to be used in detection methods or treatments and/or vaccines

Time: 2 years

No related HPO nodes (Using clinical trials)